Trump announces trade deal with EU following months of negotiations
SAN FRANCISCO—Twist Bioscience Corp (NASDAQ:TWST), a biotechnology company with a market capitalization of $3.2 billion, recently disclosed that its President and Chief Operating Officer, Finn Patrick John, executed a sale of company stock. According to a filing with the Securities and Exchange Commission, Finn sold 2,845 shares of common stock on February 3, 2025, at a price of $49.352 per share, totaling approximately $140,406. The stock has since climbed to $53.66, showing strong momentum with a 12% gain year-to-date. InvestingPro data indicates the stock is currently trading above its Fair Value.
The sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience’s equity incentive plans. Following this transaction, Finn holds 269,199 shares directly. The stock sale was not a discretionary trade by Finn, as noted in the filing. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 5.0, indicating robust liquidity. Subscribers can access 8 additional ProTips and comprehensive insider trading patterns through InvestingPro’s detailed research reports.
In other recent news, Twist Bioscience has been the focus of multiple analyst notes, highlighting the company’s strong financial performance and upward revisions of their fiscal year 2025 guidance. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the company’s price target to $62, maintaining a Sector Outperform rating, following Twist Bioscience’s first quarter results that surpassed consensus predictions and previously issued company guidance. Barclays (LON:BARC) analyst Luke Sergott also increased the price target for Twist Bioscience to $58, citing the company’s growing momentum, particularly in its Express portfolio and Next-Generation Sequencing (NGS) tools.
Baird reaffirmed its positive stance on Twist Bioscience, maintaining an Outperform rating and a $48.00 price target, highlighting the consistent pricing premiums for the company’s Express Genes service. TD Cowen maintained its Buy rating and a price target of $58.00, signaling confidence in the company’s revenue and gross margin outlook for fiscal year 2025 and beyond.
These recent developments reflect the strong performance of Twist Bioscience, with analysts from Scotiabank, Barclays, Baird, and TD Cowen all expressing confidence in the company’s financial future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.